Stockreport

Compass Therapeutics: Exciting Clinical Updates Inbound For 2026 [Seeking Alpha]

Compass Therapeutics, Inc.  (CMPX) 
PDF Tovecimig's early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX's cash runway exten [Read more]